M Ventures (Merck)

Type

CVC

Status

Active

Location

Amsterdam, Netherlands

Total investments

129

Average round size

27M

Portfolio companies

86

Rounds per year

8.60

Lead investments

30

Follow on index

0.33

Exits

8

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologyArtificial IntelligenceHealth CareMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsSemiconductorBiopharma

Summary

In 2017 was created M Ventures, which is appeared as VC. The company was established in North America in United States. The main office of represented VC is situated in the Menlo Park.

This organization was formed by Adrian Fenty, Alyson DeNardo, Mike Palank. Besides them, we counted 10 critical employees of this fund in our database.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the M Ventures, startups are often financed by 5AM Ventures, Versant Ventures, SV Angel. The meaningful sponsors for the fund in investment in the same round are Y Combinator, SR One, Novo Seeds. In the next rounds fund is usually obtained by Y Combinator, SR One, Novo Seeds.

The fund has no exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight WITHIN (VR/AR), Anaphore, DNA Script. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most popular fund investment industries, there are Software, eSports.

When the investment is from M Ventures the average startup value is 10-50 millions dollars. The fund is constantly included in 7-12 deals per year. The real fund results show that this VC is 16 percentage points less often commits exit comparing to other companies. The top activity for fund was in 2017. Despite it in 2019 the fund had an activity. The usual things for fund are deals in the range of 10 - 50 millions dollars. The top amount of exits for fund were in 2018. This M Ventures works on 28 percentage points less the average amount of lead investments comparing to the other organizations.

Show more

Investor highlights

Industry focus
Biotech/Life SciencesHealthcareClimate techHardware
Stage focus
Seed
Geo focus
Generalist

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
129
Lead investments
30
Exits
8
Rounds per year
8.60
Follow on index
0.33
Investments by industry
  • Biotechnology (77)
  • Health Care (52)
  • Therapeutics (36)
  • Medical (32)
  • Pharmaceutical (24)
  • Show 69 more
Investments by region
  • United States (50)
  • United Kingdom (18)
  • Switzerland (16)
  • France (7)
  • Israel (10)
  • Show 6 more
Peak activity year
2023
Number of Unicorns
1
Number of Decacorns
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
7
Avg. valuation at time of investment
26M
Group Appearance index
0.96
Avg. company exit year
6
Avg. multiplicator
20.58
Strategy success index
0.70

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
iOnctura 20 Jun 2024 Biotechnology, Health Care, Medical Device Early Stage Venture 94M Switzerland, Geneva, Geneva
Lightcast Discovery 17 Aug 2023 Biotechnology Early Stage Venture 52M Cambridgeshire, Cambridge, United Kingdom

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.